Shares of CollaGenex Pharmaceuticals dipped this morning after the drug developer announced it was suspending enrollment in a mid-stage study of a new acne drug after one of the patients in the trial experienced a severe adverse reaction. One of the volunteers in the trial exhibited symptoms of phototoxicity, a condition characterized by such sensitivity to sunlight it can lead to second degree burns. The patient had been given a 40 mg dose of modified tetracycline incyclinide, an antibiotic previously linked to phototoxicity. CollaGenex shares slid 16 percent on the news.
"Our principal concern is the safety of our patients, and we are suspending further enrollment in the 40 mg cohort of this trial while we investigate this adverse event," said Colin Stewart, CollaGenex president and chief executive, in a statement. "Since we observed no adverse events at lower doses, we are continuing the Phase II dose-finding trial of incyclinide for the treatment of rosacea."
- check out the announcement from CollaGenex
- see this the AP report for more information
Related Articles:
CollaGenex touts Phase IV Oracea data. Report
CollaGenex acne drug show positive Phase II results. Report